Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer - A meta-analysis

被引:496
作者
Gould, MK
Kuschner, WG
Rydzak, CE
Maclean, CC
Demas, AN
Shigemitsu, H
Chan, JK
Owens, DK
机构
[1] Vet Affairs Palo Alto Hlth Care Syst, Pulm Sect, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.7326/0003-4819-139-11-200311180-00013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To compare the diagnostic accuracy of computed tomography (CT) and positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) for mediastinal staging in patients with non-small-cell lung cancer and to determine whether test results are conditionally dependent (the sensitivity and specificity of FDG-PET depend on the presence or absence of enlarged mediastinal lymph nodes on CT). Data Sources: Computerized search of MEDLINE, EMBASE, BIOSIS, and CancerLit through March 2003 and reference lists of retrieved studies and review articles. Study Selection: Studies in any language that examined FDG-PET for mediastinal staging in patients with known or suspected non-small-cell lung cancer, enrolled at least 10 participants (including at least 5 participants with mediastinal metastasis), and provided enough data to permit calculation of sensitivity and specificity for identifying lymph node involvement. Data Extraction: One reviewer (of non-English-language studies) or 2 reviewers (of English-language studies) independently evaluated studies for inclusion, rated methodologic quality, and abstracted relevant data. Data Synthesis: Thirty-nine studies met inclusion criteria. Methodologic quality varied, but few aspects of study quality affected diagnostic accuracy. The authors constructed summary receiver-operating characteristic curves for CT and FDG-PET. Positron emission tomography with 18-fluorodeoxyglucose was more accurate than CT for identifying lymph node involvement (P < 0.001). For CT, median sensitivity and specificity were 61% (interquartile range, 50% to 71%) and 79% (interquartile range, 66% to 89%), respectively. For FDG-PET, median sensitivity and specificity were 85% (interquartile range, 67% to 91%) and 90% (interquartile range, 82% to 96%), respectively. Fourteen studies provided information about the conditional test performance of CT and FDG-PET. Positron emission tomography with 18-fluorodeoxyglucose was more sensitive but less specific when CT showed enlarged lymph nodes (median sensitivity, 100% [interquartile range, 90% to 100%]; median specificity, 78% [interquartile range, 68% to 100%]) than when CT showed no lymph node enlargement (median sensitivity, 82% [interquartile range, 65% to 100%]; median specificity, 93% [interquartile range, 92% to 100%]; P = 0.002). Conclusions: Positron emission tomography with 18-fluorodeoxyglucose is more accurate than CT for mediastinal staging. Positron emission tomography with 18-fluorodeoxyglucose is more sensitive but less specific when CT shows enlarged mediastinal lymph nodes.
引用
收藏
页码:879 / 892
页数:14
相关论文
共 109 条
[1]  
Adams S, 2000, NUKLEARMED-NUCL MED, V39, pN83
[2]   Improvement of non-small-cell lung cancer staging by means of positron emission tomography [J].
Albes, JM ;
Lietzenmayer, R ;
Schott, U ;
Schülen, E ;
Wehrmann, M ;
Ziemer, G .
THORACIC AND CARDIOVASCULAR SURGEON, 1999, 47 (01) :42-47
[3]   Value of positron emission tomography for lung cancer staging [J].
Albes, JM ;
Dohmen, BM ;
Schott, U ;
Schülen, E ;
Wehrmann, M ;
Ziemer, G .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (01) :55-62
[4]  
Begg C.B., 1994, HDB RES SYNTHESIS, P399
[5]   F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer [J].
Berlangieri, SU ;
Scott, AM ;
Knight, SR ;
Fitt, GJ ;
Hennessy, OF ;
Tochon-Danguy, HJ ;
Clarke, CP ;
McKay, WJ .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1999, 16 :S25-S30
[6]  
Bury T, 1996, REV MAL RESPIR, V13, P281
[7]   Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography [J].
Bury, T ;
Dowlati, A ;
Paulus, P ;
Hustinx, R ;
Radermecker, M ;
Rigo, P .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (02) :204-206
[8]   Staging of the mediastinum: Value of positron emission tomography imaging in non-small cell lung cancer [J].
Bury, T ;
Paulus, P ;
Dowlati, A ;
Corhay, JL ;
Weber, T ;
Ghaye, B ;
Schoffers, J ;
Limet, R ;
Albert, A ;
Rigo, P ;
Radermecker, M .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (12) :2560-2564
[9]   Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer [J].
Bury, T ;
Dowlati, A ;
Paulus, P ;
Corhay, JL ;
Hustinx, R ;
Ghaye, B ;
Radermecker, M ;
Rigo, P .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (11) :2529-2534
[10]  
Changlai SP, 2001, ONCOL REP, V8, P337